Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.42 |
| ▸ | HTR3B | O95264 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anpirtoline SCHEMBL3115824 | 0.98 | MEN1 (0.97) | MEN1KMT2ACYP1A2HTR3EHTR3B | |
| SCHEMBL16334124 | 0.84 | MEN1 (0.73) | MEN1KMT2ACYP1A2HTR3EHTR3B | |
| SCHEMBL16333873 | 0.84 | MEN1 (0.73) | MEN1KMT2ACYP1A2HTR3EHTR3B | |
| SCHEMBL13039177 | 0.80 | MEN1 (0.67) | MEN1KMT2ACYP1A2SLC18A3SIGMAR1 | |
| SCHEMBL4675115 | 0.72 | KMT2A (0.57) | MEN1KMT2ACYP1A2ALDH1A1SLC18A3 | |
| SCHEMBL23166117 | 0.72 | MEN1 (0.56) | MEN1KMT2ACYP1A2HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL4706173 | 0.71 | KMT2A (0.55) | MEN1KMT2ACYP1A2ALDH1A1SLC18A3 | |
| SCHEMBL30174508 | 0.70 | MEN1 (0.54) | MEN1KMT2ACYP1A2HTR3EHTR3B | |
| SCHEMBL24338764 | 0.70 | MEN1 (0.54) | MEN1KMT2ACYP1A2HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL20266524 | 0.69 | MEN1 (0.53) | MEN1KMT2ACYP1A2HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20130121923-A1 | Treatment of Male Sexual Dysfunction | PFIZER INC. (US) | 2013-05-16 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20110107442-A1 | Treatment of Male Sexual Dysfunction | IXCHELSIS LIMITED (GB) | 2011-05-05 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| EP-1470115-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2004-10-27 | — | — | EP | claimed |
| US-20030229001-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2003-12-11 | — | — | US | claimed |
| WO-2003064402-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-08-07 | — | — | WO | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| CN-1355698-A | Compound for medicine for treating function of bronchial contraction | RESPIRATORIUS AB (SE) | 2002-06-26 | — | — | CN | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | claimed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-1997044062-A1 | THE USE OF 5-HT1B/1D AGONISTS TO TREAT OCULAR PAIN | ALCON LABORATORIES, INC. (US) | 1997-11-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130121923-A1 | Treatment of Male Sexual Dysfunction | OXTR, AVPR1B, AVPR2 | MEN1 1452/4885KMT2A 4643/4885CYP1A2 2866/4885 |
| US-20110107442-A1 | Treatment of Male Sexual Dysfunction | OXTR, AVPR1B, AVPR2 | MEN1 1452/4885KMT2A 4643/4885CYP1A2 2866/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | MEN1 2593/4885KMT2A 1760/4885CYP1A2 692/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | MEN1 2146/4885KMT2A 2027/4885CYP1A2 90/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | MEN1 2146/4885KMT2A 2027/4885CYP1A2 90/4885 |
| US-20030229001-A1 | Treatment of male sexual dysfunction | OXTR, AVPR1B, AVPR2 | MEN1 1452/4885KMT2A 4643/4885CYP1A2 2866/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | MEN1 2146/4885KMT2A 2027/4885CYP1A2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.